Viome

Viome focuses on digitizing, decoding, and deciphering human biology for the prevention, early diagnosis, and treatment of chronic diseases and cancer. Viome uses a systems biology approach to comprehend the origin and progression of a disease through gene expression (mRNA) analysis with its AI platform. The company develops tests to assess gut and oral microbiome health and provides custom supplement formulas and tailored biotic blends to improve it. These tests are designed to determine how well the user is aging at a cellular level, and nutrition recommendations are designed to optimize the user's specific biological functions responsible for how they're aging internally.

Viome is claimed to measure over 10 million data points from expressed genes per sample from microbial (oral and gut) and human cells. Viome offers over 50 health score biomarkers included with its Full Body Intelligence Test. The scores are based on an analysis of all the gene expressions in the body, which can reveal the precise nutrition needed to address inflammation and microbial imbalance. 

The company also produces custom-formulated blends and ships them to customers on a monthly basis. These are offered in the form of supplements, gut biotic blends, and oral biotic lozenges. These are personalized to customers based on the results of full-body intelligence, gut intelligence, and oral intelligence tests, respectively.

In November 2023, Viome Life Sciences acquired Naring Health, a digital health and wellness company focused on providing access to individualized clinical and molecular data. The acquisition also included Naring Health’s health monitoring company, DiscernDx, and food science company Foodome. After the acquisition, Viome intended to enhance its suite of personalized health solutions by using combined resources, including key patents and intellectual property.

Key customers and partnerships

Viome entered a partnership with pharmacy chain CVS in August 2023 to expand its product distribution, thereby making its tests available in 200 CVS stores across the US.

Funding and financials

In October 2023, the company raised USD 86.5 million in a Series C funding round co-led by Khosla Ventures and Bold Capital. The company expected to use the funds for business and market expansion.